| 吴 祎,张海航,杨思维,李 云,卢彦达.贝伐珠单抗注射液联合TACE对中晚期肝细胞癌患者肿瘤标志物、血管生成因子和凋亡分子的影响[J].现代生物医学进展英文版,2024,(13):2596-2600. |
| 贝伐珠单抗注射液联合TACE对中晚期肝细胞癌患者肿瘤标志物、血管生成因子和凋亡分子的影响 |
| Effects of Bevacizumab Injection Combined with TACE on Tumor Markers, Angiogenic Factors and Apoptotic Molecules in Patients with Middle to Late Stage Hepatocellular Carcinoma |
| Received:January 08, 2024 Revised:January 31, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.13.038 |
| 中文关键词: 贝伐珠单抗注射液 肝动脉化疗栓塞术 中晚期肝细胞癌 肿瘤标志物 血管生成因子 凋亡分子 |
| 英文关键词: Bevacizumab injection Transcatheter arterial chemoembolization Middle to late stage hepatocellular carcinoma Tumor markers Angiogenetic factors Apoptosis molecules |
| 基金项目:海南省自然基金高层次人才项目（821RC695） |
|
| Hits: 193 |
| Download times: 121 |
| 中文摘要: |
| 摘要 目的：探讨贝伐珠单抗注射液联合肝动脉化疗栓塞术（TACE）对中晚期肝细胞癌（HCC）患者肿瘤标志物、血管生成因子和凋亡分子的影响。方法：采用随机数字表法将2021年9月～2023年4月期间我院收治的142例中晚期HCC患者分为对照组（n=71，TACE治疗）和研究组（n=71，贝伐珠单抗注射液联合TACE治疗）。对比两组疗效、血清肿瘤标志物[甲胎蛋白（AFP）、癌胚抗原（CEA）、α-L-岩藻糖苷酶（AFU）、糖类抗原19-9（CA19-9）]、血管生成因子指标[肝细胞生长因子（HGF）、血管内皮生长因子（VEGF）、结缔组织生长因子（CTGF）、缺氧诱导因子-1α（HIF-1α）]和凋亡分子[B淋巴细胞瘤-2（Bcl-2）、Bcl-2相关X蛋白基因（Bax）、生存素（Survivin）、C-半胱氨酸-天冬氨酸蛋白酶10（Caspase10）]变化情况，并观察两组不良反应发生率。结果：研究组的客观缓解率（ORR）、疾病控制率（DCR）明显高于对照组（P<0.05）。治疗6周后，两组AFP、CEA、AFU、CA19-9、HGF、VEGF、CTGF、HIF-1α、Bcl-2、Survivin下降，Bax、Caspase10升高，且研究组的改善幅度大于对照组（P<0.05）。对照组的不良反应发生率为12.69%，研究组的为19.73%，组间比较无差异（P>0.05）。结论：贝伐珠单抗注射液联合TACE治疗中晚期HCC患者，可有效降低肿瘤标志物水平，减少血管生成，促进HCC癌细胞凋亡。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of bevacizumab injection combined with transcatheter arterial chemoembolization (TACE) on tumor markers, angiogenic factors and apoptotic molecules in patients with middle to late stage hepatocellular carcinoma (HCC). Methods: Random number table method was used, 142 patients with middle to late stage HCC who were admitted to our hospital from September 2021 to April 2023 were divided into control group (n=71, TACE treatment) and study group (n=71, bevacizumab injection combine with TACE treatment). The efficacy, serum tumor markers [alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), α-L-fucosidase (AFU), carbohydrate antigen 19-9 (CA19-9)], angiogenesis factors [hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), hypoxia-inducible factor-1α(HIF-1α)] and apoptotic molecules [B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein gene (Bax), survivin (Survivin), C-cysteine-aspartate protease 10 (Caspase10)] were compared between two groups, the incidence of adverse reactions in two groups was observed. Results: The objective response rate (ORR) and disease control rate (DCR) in study group were significantly higher than those in control group (P<0.05). 6 weeks after treatment, AFP, CEA, AFU, CA19-9, HGF, VEGF, CTGF, HIF-1α, Bcl-2 and Survivin in two groups decreased, Bax and Caspase10 in two groups increased, and the improvement in the study group was greater than that in the control group(P<0.05). The incidence of adverse reactions in the control group was 12.69%, while in the study group was 19.73%, there was no significant difference between the groups (P>0.05). Conclusion: The combination of bevacizumab injection and TACE in the treatment of advanced HCC patients can effectively reduce tumor marker levels, reduce angiogenesis, and promote HCC cancer cell apoptosis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
